A bicameral coalition of 27 Nevada lawmakers has introduced a resolution urging the U.S. Congress to take action on the therapeutic use of psilocybin, psilocin, DMT, ibogaine, mescaline, and MDMA.
Nevada State Capitol.
Filed yesterday with 27 bicameral sponsors, Senate Joint Resolution 10 was referred to the Committee on Legislative Operations and Elections for further consideration.
SJR10 highlights the growing body of research supporting the use of psychedelics such as psilocybin, MDMA, DMT, ibogaine, and mescaline for treating conditions including post-traumatic stress disorder (PTSD), treatment-resistant depression, and substance use disorders. The resolution points to clinical trials demonstrating significant improvements in mental health outcomes for veterans, first responders, and others suffering from these conditions.
The resolution calls on Congress to increase federal funding for research into the therapeutic applications of psychedelic compounds, particularly for treating mental health conditions, substance use disorders, and chronic pain. It urges the establishment of a streamlined approval process for psychedelic research while maintaining appropriate safety protocols and oversight. Additionally, it seeks to create a compassionate use pathway for psychedelic investigational drugs under the Right to Try Act, ensuring proper safeguards remain in place.
The measure also calls for rescheduling psilocybin, psilocin, DMT, ibogaine, mescaline, and MDMA to classifications that better reflect their therapeutic value, low abuse potential, and safety under medical supervision—with priority given to compounds granted Breakthrough Therapy designation by the U.S. Food and Drug Administration. Furthermore, the resolution advocates for legal protections against federal prosecution for individuals and entities complying with state laws on supervised psychedelic use and proposes requiring states to form research partnerships with the U.S. Attorney General under the Controlled Substances Act to study the public health outcomes of such programs.
The Nevada Legislature also expresses support for expanded psychedelic research at qualified institutions within the state.
Upon passage, the resolution directs the Secretary of the Senate to send copies to the President of the United States, the Vice President, the Speaker of the House, each member of the Nevada Congressional Delegation, the Administrator of the U.S. Drug Enforcement Administration, and the Director of the National Institutes of Health. The resolution would take effect immediately upon passage.
